Arbaclofen placarbil: Completed Phase III enrollment

XenoPort disclosed in its 4Q12 earnings that it completed enrollment in a double-blind, placebo-controlled, U.S. Phase III trial evaluating twice-daily

Read the full 202 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE